Immatics N.V. completed an underwritten public offering of 15,535,100 ordinary shares and pre-funded warrants to purchase 4,315,304 additional shares on August 26, 2026. The transaction included the full exercise of the underwriters' option to purchase 2,589,814 extra shares. Net proceeds totaled approximately $161.1 million after deducting underwriting discounts and offering expenses. Immatics intends to use these funds for research and development, manufacturing, commercialization efforts, and general corporate purposes.

Immatics N.V. reported second quarter 2026 financial results, posting a net loss of €62.5 million ($71.2 million) on collaboration revenue of €9.1 million ($10.4 million). The company holds $448.2 million in cash and other financial assets as of June 30, 2026. Immatics announced protocol amendments for its Phase 3 SUPRAME trial of anzu-cel in advanced melanoma, shifting to a streamlined final analysis with top-line data expected in the first half of 2027, followed by a BLA submission in 2027. The company also appointed Jim Pepin as General Counsel and Corporate Secretary effective July 20, 2026, succeeding Edward Sturchio. Immatics N.V. operates in the biotechnology industry, developing precision cancer therapies targeting the PRAME antigen.